JP2001511148A - 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用 - Google Patents
免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用Info
- Publication number
- JP2001511148A JP2001511148A JP53306798A JP53306798A JP2001511148A JP 2001511148 A JP2001511148 A JP 2001511148A JP 53306798 A JP53306798 A JP 53306798A JP 53306798 A JP53306798 A JP 53306798A JP 2001511148 A JP2001511148 A JP 2001511148A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- microparticles
- poly
- lactide
- glycolide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ポリ(α-ヒドロキシ酸)マイクロパーティクルに吸着された、選択されたウ イルス抗原および薬学的に受容可能な賦形剤を含む、組成物。 2.前記マイクロパーティクルが、ポリ(L-ラクチド)、ポリ(D,L-ラクチド)、お よびポリ(D,L-ラクチド-コ-グリコリド)からなる群より選択されるポリ(α-ヒド ロキシ酸)から形成される、請求項1に記載の組成物。 3.前記マイクロパーティクルがポリ(D,L-ラクチド-コ-グリコリド)から形成さ れる、請求項2に記載の組成物。 4.前記選択された抗原がgp120である、請求項1〜3のいずれかに記載の組成 物。 5.前記選択された抗原がp24gagである、請求項1〜3のいずれかに記載の組成 物。 6.前記選択された抗原がインフルエンザA赤血球凝集素抗原である、請求項1 〜3のいずれかに記載の組成物。 7.脊椎動物被験体に、治療的有効量のポリ(α-ヒドロキシ酸)マイクロパーテ ィクルに吸着された選択されたウイルス抗原を投与する工程を包含する、免疫の 方法。 8.前記マイクロパーティクルが、ポリ(L-ラクチド)、ポリ(D,L-ラクチド)、お よびポリ(D,L-ラクチド-コ-グリコリド)からなる群より選択されるポリ(α-ヒド ロキシ酸)から形成される、請求項7に記載の方法。 9.前記マイクロパーティクルがポリ(D,L-ラクチド-コ-グリコリド)から形成さ れる、請求項8に記載の方法。 10.前記選択された抗原がgp120である、請求項7〜9のいずれかに記載の方 法。 11.前記選択された抗原がp24gagである、請求項7〜9のいずれかに記載の方 法。 12.前記選択された抗原がインフルエンザA赤血球凝集素抗原である、請求項 7〜9のいずれかに記載の方法。 13.サブミクロンの水中油エマルジョンを前記被験体に投与する工程をさらに 包含する、請求項7〜9のいずれかに記載の方法。 14.脊椎動物被験体に、ポリ(α-ヒドロキシ酸)マイクロパーティクルに吸着 された治療的有効量の選択されたウイルス抗原を投与する工程を包含する、脊椎 動物被験体において細胞性免疫応答を誘発するための方法。 15.前記マイクロパーティクルが、ポリ(L-ラクチド)、ポリ(D,L-ラクチド)、 およびポリ(D,L-ラクチド-コ-グリコリド)からなる群より選択されるポリ(α-ヒ ドロキシ酸)から形成される、請求項14に記載の方法。 16.前記マイクロパーティクルがポリ(D,L-ラクチド-コ-グリコリド)から形成 される、請求項15に記載の方法。 17.前記選択された抗原がgp120である、請求項14〜16のいずれかに記載 の方法。 18.前記選択された抗原がp24gagである、請求項14〜16のいずれかに記載 の方法。 19.前記選択された抗原がインフルエンザA赤血球凝集素抗原である、請求項 14〜16のいずれかに記載の方法。 20.脊椎動物被験体の免疫に有用な医薬の製造における、請求項1〜6のいず れかに記載の組成物の使用。 21.細胞性免疫応答が脊椎動物被験体において誘発される、請求項20に記載 の使用。 22.(a)ウイルス抗原を提供する工程; (b)該ウイルス抗原をポリ(α-ヒドロキシ酸)マイクロパーティクルに吸着させ る工程;および (c)吸着抗原を有する該マイクロパーティクルを薬学的に受容可能な賦形剤と 組み合わせる工程、 を包含する、組成物の製造法。 23.前記マイクロパーティクルが、ポリ(L-ラクチド)、ポリ(D,L-ラクチド)、 およびポリ(D,L-ラクチド-コ-グリコリド)からなる群より選択されるポリ(α-ヒ ドロキシ酸)から形成される、請求項22に記載の方法。 24.前記マイクロパーティクルがポリ(D,L-ラクチド-コ-グリコリド)から形成 される、請求項23に記載の方法。 25.前記選択された抗原がgp120である、請求項22〜24のいずれかに記載 の方法。 26.前記選択された抗原がp24gagである、請求項22〜24のいずれかに記載 の方法。 27.前記選択された抗原がインフルエンザA赤血球凝集素抗原である、請求項 22〜24のいずれかに記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3631697P | 1997-01-30 | 1997-01-30 | |
US60/036,316 | 1997-01-30 | ||
US6974997P | 1997-12-16 | 1997-12-16 | |
US60/069,749 | 1997-12-16 | ||
PCT/US1998/001738 WO1998033487A1 (en) | 1997-01-30 | 1998-01-29 | Use of microparticles with adsorbed antigen to stimulate immune responses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008308030A Division JP2009102338A (ja) | 1997-01-30 | 2008-12-02 | 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001511148A true JP2001511148A (ja) | 2001-08-07 |
JP2001511148A5 JP2001511148A5 (ja) | 2005-09-08 |
JP5037747B2 JP5037747B2 (ja) | 2012-10-03 |
Family
ID=26713053
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53306798A Expired - Fee Related JP5037747B2 (ja) | 1997-01-30 | 1998-01-29 | 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用 |
JP2008308030A Withdrawn JP2009102338A (ja) | 1997-01-30 | 2008-12-02 | 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008308030A Withdrawn JP2009102338A (ja) | 1997-01-30 | 2008-12-02 | 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用 |
Country Status (13)
Country | Link |
---|---|
US (2) | US7597908B2 (ja) |
EP (1) | EP0991403B1 (ja) |
JP (2) | JP5037747B2 (ja) |
AT (1) | ATE235890T1 (ja) |
AU (1) | AU747577B2 (ja) |
CA (1) | CA2279204C (ja) |
DE (1) | DE69812941T2 (ja) |
DK (1) | DK0991403T3 (ja) |
ES (1) | ES2195317T3 (ja) |
HK (1) | HK1023507A1 (ja) |
NZ (1) | NZ337054A (ja) |
PT (1) | PT991403E (ja) |
WO (1) | WO1998033487A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002521425A (ja) * | 1998-07-29 | 2002-07-16 | カイロン コーポレイション | 吸着表面を有する微小粒子、それを作製する方法、およびその使用 |
JP2006507213A (ja) * | 2002-02-20 | 2006-03-02 | カイロン コーポレイション | 吸着したポリペプチド含有分子を有する微粒子 |
JP2007521321A (ja) * | 2003-09-22 | 2007-08-02 | ビオメリュー | 生体再吸収性微粒子の製造方法、得た微粒子及びその使用 |
JP2009515859A (ja) * | 2005-11-14 | 2009-04-16 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク(セエヌエールエス) | コロイド性合成生体吸収性ベクターとウイルスベクターを含む組成物 |
JP2014524474A (ja) * | 2011-08-22 | 2014-09-22 | ナノバイオ コーポレーション | 単純ヘルペスウイルスのナノエマルジョンワクチン |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100372375B1 (ko) | 1993-12-23 | 2003-04-21 | 머클한스피터 | 면역반응의강화방법 |
US20040202680A1 (en) * | 1997-01-30 | 2004-10-14 | O'hagan Derek | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
ATE235890T1 (de) | 1997-01-30 | 2003-04-15 | Chiron Corp | Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
CA2363141C (en) * | 1999-02-26 | 2010-04-06 | Chiron Corporation | Microemulsions with adsorbed macromolecules and microparticles |
JP2002538195A (ja) * | 1999-03-08 | 2002-11-12 | パウダージェクト リサーチ リミテッド | 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達 |
US7713739B1 (en) | 2000-11-17 | 2010-05-11 | Novartis Vaccines And Diagnostics, Inc. | Microparticle-based transfection and activation of dendritic cells |
GB0000001D0 (en) * | 2000-01-05 | 2000-02-23 | Du Pont Uk | Pharmaceutical compositions and their preparation |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
GB0006770D0 (en) * | 2000-03-22 | 2000-05-10 | Secr Defence | Vaccine composition |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US20040022814A1 (en) * | 2000-06-15 | 2004-02-05 | O'hagan Derek | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
AUPR011700A0 (en) * | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
CN101428006A (zh) * | 2000-09-28 | 2009-05-13 | 诺华疫苗和诊断公司 | 微粒体组合物及其生产方法 |
ES2260291T3 (es) * | 2000-09-28 | 2006-11-01 | Chiron Corporation | Microparticulas para la administracion de acidos nucleicos heterologos. |
US6887857B2 (en) | 2001-04-27 | 2005-05-03 | Scimed Life Systems, Inc. | Microparticle protection of therapeutic agents |
DE10125731A1 (de) * | 2001-05-17 | 2003-03-06 | A I D Autoimmun Diagnostika Gm | Darreichungsform von immunologischen Wirkstoffen |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
JP2005514393A (ja) | 2001-12-19 | 2005-05-19 | ネクター セラピューティクス | アミノグリコシドの肺への供給 |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
CA2823937A1 (en) | 2002-10-07 | 2004-04-22 | Novartis Vaccines And Diagnostics, Inc. | Hiv vaccine formulations |
PT2279746E (pt) | 2002-11-15 | 2013-12-09 | Novartis Vaccines & Diagnostic | Proteínas de superfície de neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
WO2004060396A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
ES2596553T3 (es) | 2003-06-02 | 2017-01-10 | Glaxosmithkline Biologicals Sa | Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido |
CA2588089C (en) | 2004-11-15 | 2015-06-23 | Novartis Vaccines And Diagnostics Inc. | Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant |
PT1951299E (pt) | 2005-11-04 | 2012-02-28 | Novartis Vaccines & Diagnostic | Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores |
CA2643322C (en) | 2006-02-24 | 2015-07-21 | Novartis Ag | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
JP2011506334A (ja) | 2007-12-07 | 2011-03-03 | ノバルティス アーゲー | 免疫応答を誘導するための組成物 |
KR20130121699A (ko) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | 상호작용 혼성 비동기 컴퓨터 게임 기반구조 |
MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
MX350198B (es) | 2011-07-06 | 2017-08-30 | Novartis Ag | Emulsiones aceite en agua que contienen acidos nucleicos. |
US9782520B2 (en) | 2011-09-26 | 2017-10-10 | BioSpheres, Inc. | Reduction of implant infection via tunable stimulation of localized adaptive immune response |
US20210154144A1 (en) * | 2018-03-02 | 2021-05-27 | University Of The Sciences | Polymer compositions for storage and release of polypeptides |
EP3581201A1 (en) | 2018-06-15 | 2019-12-18 | GlaxoSmithKline Biologicals S.A. | Escherichia coli o157:h7 proteins and uses thereof |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4413057A (en) | 1980-04-14 | 1983-11-01 | Merck & Co., Inc. | Group B streptococcal capsular polysaccharides |
US4534996A (en) | 1981-03-30 | 1985-08-13 | California Institute Of Technology | Hybrid microspheres |
JPS6150378A (ja) * | 1984-08-20 | 1986-03-12 | Mitsui Toatsu Chem Inc | 非晶質太陽電池の製法 |
US5151266A (en) * | 1985-08-20 | 1992-09-29 | Neorx Corporation | Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies |
US5151225A (en) | 1989-05-01 | 1992-09-29 | Hoover Treated Wood Products, Inc. | Flame retardant composition and method for treating wood |
DK0474727T3 (da) | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 ekstracellulært domæne |
US5010183A (en) | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
EP0444181B2 (en) | 1989-08-04 | 2010-11-24 | Bayer Schering Pharma Aktiengesellschaft | C-erbb-2 external domain: gp75 |
DK0596032T4 (da) | 1991-07-25 | 2004-07-26 | Idec Pharma Corp | Induktion af cytotoksiske T-lymfocytsvar |
DE69219787T2 (de) | 1991-11-29 | 1997-08-28 | Viagene Inc | Immuntherapeutische vektorkonstrukte gegen krebs |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
JPH08505625A (ja) * | 1993-01-11 | 1996-06-18 | ダナ−ファーバー キャンサー インスティチュート | 細胞毒性tリンパ球応答の誘導 |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
GB9311454D0 (en) * | 1993-06-03 | 1993-07-21 | Agricultural & Food Res | Pharmaceutical compositions |
US5643605A (en) | 1993-10-25 | 1997-07-01 | Genentech, Inc. | Methods and compositions for microencapsulation of adjuvants |
US5902565A (en) | 1993-12-24 | 1999-05-11 | Csl Limited | Spray dried vaccine preparation comprising aluminium adsorbed immunogens |
CA2190121A1 (en) | 1994-03-15 | 1995-09-21 | Edith Mathiowitz | Polymeric gene delivery system |
WO1995032000A1 (en) | 1994-05-20 | 1995-11-30 | Microgenesys, Inc. | Hiv polyprotein immunogens |
GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US5827531A (en) | 1994-12-02 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microcapsules and methods for making |
WO1996020698A2 (en) * | 1995-01-05 | 1996-07-11 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Surface-modified nanoparticles and method of making and using same |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
WO1996026277A1 (en) * | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
US5714354A (en) | 1995-06-06 | 1998-02-03 | American Home Products Corporation | Alcohol-free pneumococcal polysaccharide purification process |
GB9514285D0 (en) * | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
US5630922A (en) | 1995-12-26 | 1997-05-20 | Ppg Industries, Inc. | Electrodepositable coating composition containing diorganotin dicarboxylates |
EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
GB9619002D0 (en) | 1996-09-11 | 1996-10-23 | Oxford Biosciences Ltd | Particle delivery |
US5783567A (en) | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
ATE235890T1 (de) | 1997-01-30 | 2003-04-15 | Chiron Corp | Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr |
ATE441432T1 (de) | 1997-03-10 | 2009-09-15 | Ottawa Hospital Res Inst | Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien |
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
PT1042001E (pt) | 1997-12-16 | 2002-09-30 | Chiron Corp | Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua |
US7060284B1 (en) | 1999-08-03 | 2006-06-13 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
US20040022814A1 (en) | 2000-06-15 | 2004-02-05 | O'hagan Derek | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
CN101428006A (zh) | 2000-09-28 | 2009-05-13 | 诺华疫苗和诊断公司 | 微粒体组合物及其生产方法 |
AR045702A1 (es) * | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
-
1998
- 1998-01-29 AT AT98904760T patent/ATE235890T1/de active
- 1998-01-29 NZ NZ337054A patent/NZ337054A/xx not_active IP Right Cessation
- 1998-01-29 AU AU62557/98A patent/AU747577B2/en not_active Ceased
- 1998-01-29 JP JP53306798A patent/JP5037747B2/ja not_active Expired - Fee Related
- 1998-01-29 PT PT98904760T patent/PT991403E/pt unknown
- 1998-01-29 EP EP98904760A patent/EP0991403B1/en not_active Expired - Lifetime
- 1998-01-29 CA CA002279204A patent/CA2279204C/en not_active Expired - Fee Related
- 1998-01-29 DE DE69812941T patent/DE69812941T2/de not_active Expired - Lifetime
- 1998-01-29 WO PCT/US1998/001738 patent/WO1998033487A1/en active IP Right Grant
- 1998-01-29 DK DK98904760T patent/DK0991403T3/da active
- 1998-01-29 ES ES98904760T patent/ES2195317T3/es not_active Expired - Lifetime
-
2000
- 2000-05-02 HK HK00102619A patent/HK1023507A1/xx not_active IP Right Cessation
-
2002
- 2002-07-03 US US10/189,104 patent/US7597908B2/en not_active Expired - Fee Related
-
2008
- 2008-12-02 JP JP2008308030A patent/JP2009102338A/ja not_active Withdrawn
-
2009
- 2009-10-06 US US12/573,903 patent/US20100021548A1/en not_active Abandoned
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002521425A (ja) * | 1998-07-29 | 2002-07-16 | カイロン コーポレイション | 吸着表面を有する微小粒子、それを作製する方法、およびその使用 |
JP2006507213A (ja) * | 2002-02-20 | 2006-03-02 | カイロン コーポレイション | 吸着したポリペプチド含有分子を有する微粒子 |
JP2010070555A (ja) * | 2002-02-20 | 2010-04-02 | Novartis Vaccines & Diagnostics Inc | 吸着したポリペプチド含有分子を有する微粒子 |
JP4646516B2 (ja) * | 2002-02-20 | 2011-03-09 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 吸着したポリペプチド含有分子を有する微粒子 |
JP2013231069A (ja) * | 2002-02-20 | 2013-11-14 | Novartis Vaccines & Diagnostics Inc | 吸着したポリペプチド含有分子を有する微粒子 |
JP2016006109A (ja) * | 2002-02-20 | 2016-01-14 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 吸着したポリペプチド含有分子を有する微粒子 |
JP2007521321A (ja) * | 2003-09-22 | 2007-08-02 | ビオメリュー | 生体再吸収性微粒子の製造方法、得た微粒子及びその使用 |
JP2009515859A (ja) * | 2005-11-14 | 2009-04-16 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク(セエヌエールエス) | コロイド性合成生体吸収性ベクターとウイルスベクターを含む組成物 |
JP2014524474A (ja) * | 2011-08-22 | 2014-09-22 | ナノバイオ コーポレーション | 単純ヘルペスウイルスのナノエマルジョンワクチン |
US11147869B2 (en) | 2011-08-22 | 2021-10-19 | Bluewillow Biologics, Inc. | Herpes simplex virus nanoemulsion vaccine |
Also Published As
Publication number | Publication date |
---|---|
CA2279204A1 (en) | 1998-08-06 |
DK0991403T3 (da) | 2003-07-28 |
US7597908B2 (en) | 2009-10-06 |
ATE235890T1 (de) | 2003-04-15 |
US20100021548A1 (en) | 2010-01-28 |
JP5037747B2 (ja) | 2012-10-03 |
US20030049298A1 (en) | 2003-03-13 |
AU6255798A (en) | 1998-08-25 |
DE69812941D1 (de) | 2003-05-15 |
EP0991403B1 (en) | 2003-04-02 |
DE69812941T2 (de) | 2004-02-05 |
ES2195317T3 (es) | 2003-12-01 |
NZ337054A (en) | 2001-03-30 |
EP0991403A1 (en) | 2000-04-12 |
JP2009102338A (ja) | 2009-05-14 |
CA2279204C (en) | 2005-11-15 |
PT991403E (pt) | 2003-08-29 |
AU747577B2 (en) | 2002-05-16 |
HK1023507A1 (en) | 2000-09-15 |
WO1998033487A1 (en) | 1998-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5037747B2 (ja) | 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用 | |
JP4918188B2 (ja) | サブミクロンの水中油型エマルジョンと合わせた微粒子の使用 | |
JP4601168B2 (ja) | 吸着表面を有する微小粒子、それを作製する方法、およびその使用 | |
RU2257198C2 (ru) | Композиции микрочастиц и способы их получения | |
JP6073053B2 (ja) | 吸着された高分子および微粒子を有するミクロエマルジョン | |
US8021834B2 (en) | Use of microparticles combined with submicron oil-in-water emulsions | |
JP2003511420A (ja) | タンパク質から細胞性免疫応答を得る方法 | |
JP4646516B2 (ja) | 吸着したポリペプチド含有分子を有する微粒子 | |
O'Hagan | Recent advances in immunological adjuvants: the development of particulate antigen delivery systems | |
EP1275380A1 (en) | Use of microparticles with adsorbed antigen to stimulate immune responses | |
PT1585542E (pt) | Composições imunogénicas contendo fosfolípido |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050112 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080603 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080902 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081002 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081030 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081204 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20081204 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090619 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090820 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090827 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110524 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110602 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110624 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110705 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110722 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120518 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120705 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150713 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |